foto london banner.jpg

Something Powerful

Tell The Reader More

The headline and subheader tells us what you're offering, and the form header closes the deal. Over here you can explain why your offer is so great it's worth filling out a form for.

Remember:

  • Bullets are great
  • For spelling out benefits and
  • Turning visitors into leads.

Avacta looks to deals to leverage Affimer platform...

Key learnings: UK-based Avacta Group has developed Affimer® technology, an ...

Read More

Building a thriving life sciences hub in the Nordi...

On Thursday 30 August, an expert panel will take to the stage at the inaugu...

Read More

Unlocking Potential in the Nordic Life Sciences Se...

In 2017, life science companies in Scandinavia raised almost $2.2 billion t...

Read More

Novoheart expands global presence to support comme...

Key learnings: Novoheart has developed human bioengineered heart constructs...

Read More

PhoreMost raises £11m Series A round to progress t...

Key learnings: PhoreMost completed its Series A round in May 2018, with a t...

Read More

Cognetivity’s AI-driven cognitive test seeks to ad...

Key learnings: Cognetivity Neurosciences was named joint winner in the Inno...

Read More

Grace cooling device marries design and automation...

Key learnings: Cooling device, Grace, won the Peri-Menopause Challenge cate...

Read More

Have your say in the LSX C-Suite Challenges in Lif...

What are the biggest obstacles to securing financing? What challenges do yo...

Read More

CMS: Addressing life science challenges through se...

Key learnings: Law firm CMS advises a wide spectrum of life sciences client...

Read More

£29m Series B spurs Enterprise Therapeutics’ muco-...

Key learnings:

Read More

Overcoming commercialisation challenges in advance...

Learn more about the commercialisation of advanced therapies in the on-dema...

Read More

On-demand Webinar Series: Funding, Commercialisati...

Learn more about the key funding, commercialisation, and market access chal...

Read More

Add Your Response